ADA Review, Retatrutide Access and GLP-1 Generics Lead a Busy Diabetes Week

This Week in Diabetes and Obesity Drugs: ADA Review, Retatrutide Access, FDA Guidance

The American Diabetes Association is reviewing the removal of five prominent experts by police at this year's annual meeting. In a statement, the organization said its Audit and Governance Committee is examining the incident and preparing recommendations for how the ADA should respond. In a separate analysis, the ADA projects that nearly 500,000 Medicaid beneficiaries with diabetes could lose healthcare coverage by 2034 unless policymakers intervene.

Obesity and diabetes drug developers dominated the week's news. Eli Lilly said it will allow more patients to apply for early access to retatrutide, its investigational obesity drug, weeks after granting a single 79-year-old patient special compassionate access. Novo Nordisk, meanwhile, faces a shareholder lawsuit alleging it misled investors about trial results for its investigational weight-loss drug CagriSema, and separately announced that its IL-6 inhibitor ziltivekimab failed to cut major adverse cardiovascular events in a phase III trial involving patients with atherosclerotic cardiovascular disease, chronic kidney disease and cardiovascular inflammation.

Regulators also moved. The FDA approved Garzulys (insulin aspart-fsan), a rapid-acting biosimilar to NovoLog from Meitheal Pharmaceuticals, for adults and pediatric patients with diabetes. The agency also issued draft guidance aimed at making generic versions of blockbuster GLP-1 drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). A review in JAMA Internal Medicine found that continuous glucose monitoring produces a modest average HbA1c reduction of about 0.3% in adults with type 2 diabetes.

Elsewhere in the week's news: once-weekly somapacitan (Sogroya) was noninferior to daily growth hormone injections in a phase III trial of girls with Turner syndrome; plastic surgeons report more patients seeking treatment for temporal hollowing after GLP-1 use; actor Ethan Suplee cautioned about GLP-1 drugs after losing 300 pounds; some women are crediting the drugs with helping them conceive; and separation hearings for transgender service members challenging last year's military ban are being held behind closed doors.

What the Retatrutide Expansion, CagriSema Suit and Generics Guidance Signal

Obesy Drug Competition Is Heating Up on Multiple Fronts

Eli Lilly's decision to widen early access to retatrutide signals confidence in its pipeline and adds pressure on Novo Nordisk, whose CagriSema is now tied to a shareholder lawsuit over how trial results were described. The retatrutide move follows a high-profile compassionate-use case, suggesting Lilly is eager to build momentum and real-world experience while the drug is still investigational. Novo's separate phase III failure for ziltivekimab removes a potential source of diversification at a time when its metabolic franchise faces legal and competitive questions. Interpretation: none of these events settles the obesity market, but together they point to a race in which access, data disclosure and pipeline breadth are becoming competitive weapons.

FDA Draft Guidance Could Redraw the GLP-1 Pricing Map

The FDA's draft guidance on generic semaglutide and tirzepatide is the most consequential regulatory signal of the week. If finalized, it would create a pathway for lower-cost alternatives to two of the best-selling drugs in the world, potentially expanding access in Medicaid and other budget-constrained systems. The approval of Garzulys, the third biosimilar to NovoLog, shows the same dynamic already at work in insulin. That said, the guidance is only a draft, and any generics would still face manufacturing, patent and bioequivalence hurdles. The practical effect is likely to be felt in pricing negotiations before actual generic entries hit the market.

Access and Evidence Are the Real Bottlenecks

The ADA's projection that nearly 500,000 Medicaid beneficiaries with diabetes could lose coverage by 2034 puts the access problem in stark terms. Early-access programs like Lilly's retatrutide expansion help a small number of patients, but they do not replace broad coverage. Meanwhile, the JAMA Internal Medicine review's finding of a modest average HbA1c benefit of about 0.3% from continuous glucose monitoring is a reminder that even widely adopted tools have limited average effects — useful context for payers deciding what to cover.

Reputation and Side-Effect Signals Matter Too

The ADA's police incident review, plastic surgeons' reports of temporal hollowing after GLP-1 use, actor Ethan Suplee's public caution and social media stories about GLP-1-related pregnancies all feed the broader conversation about these drugs. None of these anecdotes is evidence of harm or benefit on its own, but they can shape patient perceptions and, over time, prescribing and regulatory behavior. The ADA's handling of its own governance issue will test the organization's credibility with members and the wider medical community.

What Patients, Clinicians and Investors Should Watch Next

For patients and families:

• Ask whether you may qualify for Eli Lilly's expanded retatrutide early-access program; specific eligibility criteria have not been published, so check with your clinician or the company.
• Watch for FDA action on generic semaglutide and tirzepatide; final guidance could eventually lower out-of-pocket costs, but no generic is on the market yet.
• If you use rapid-acting insulin, Garzulys (insulin aspart-fsan) is now an FDA-approved alternative to NovoLog; ask your prescriber whether a switch is appropriate for your regimen.

For clinicians:

• Set realistic expectations for continuous glucose monitoring: the JAMA Internal Medicine review found an average HbA1c reduction of about 0.3% in adults with type 2 diabetes.
• Be alert to reported side effects such as temporal hollowing after GLP-1 use, and discuss fertility-related anecdotes with patients considering these drugs.

For investors:

• Track Novo Nordisk's response to the CagriSema shareholder lawsuit and any disclosures tied to ziltivekimab's phase III failure.
• Follow Eli Lilly's retatrutide early-access expansion and the FDA's progress on GLP-1 generic guidance.